Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2021
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Journal of Crohn'S & Colitis
|
January 20, 2016
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
L Marthey, C Mateus, C Mussini, et al.
Cancer Immunology, Immunotherapy : CII
|
April 17, 2023
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas
E Toulemonde, S Chevret, M Battistella, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld, et al.
British Journal of Cancer
|
May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
C Le Tourneau, B Dreno, Y Kirova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma
A Arance, M-A Berciano-Guerrero, J Guo, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS)
R Saúde-Conde, T Vandamme, M De Backer, et al.
The British Journal of Dermatology
|
July 8, 2015
Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group
C Hurabielle, S Ingen-Housz-Oro, N Ortonne, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2021
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Journal of Crohn'S & Colitis
|
January 20, 2016
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
L Marthey, C Mateus, C Mussini, et al.
Cancer Immunology, Immunotherapy : CII
|
April 17, 2023
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas
E Toulemonde, S Chevret, M Battistella, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld, et al.
British Journal of Cancer
|
May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
C Le Tourneau, B Dreno, Y Kirova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma
A Arance, M-A Berciano-Guerrero, J Guo, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS)
R Saúde-Conde, T Vandamme, M De Backer, et al.
The British Journal of Dermatology
|
July 8, 2015
Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group
C Hurabielle, S Ingen-Housz-Oro, N Ortonne, et al.
Page
of 10